Skip to Main Content
Sign in to myUHN Patient Portal

Clinical Trials Search Results

 

 

423692507542/16/2018 5:34:22 PMThe breast MRI is used in the preoperative scenario to evaluate the extension of a newly diagnosed breast cancer and to screen the contralateral breast STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:34:22 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423694402532/16/2018 5:33:38 PMincluding a synchronous contralateral breast cancer (Note Patients found to have a contralateral breast cancer on study imaging following STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:33:38 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423642217932/16/2018 5:24:12 PMwidespread acceptance for use in breast reconstruction and other areas and has the potential to provide support to the breast implant without tissue expansion in a STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:24:12 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423761588522/16/2018 5:33:36 PMwho are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:33:36 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423637574352/16/2018 5:25:21 PMALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging but is not specific enough to detect a difference across all breast tumor types STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:25:21 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423582574442/16/2018 5:25:40 PM2. Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of Benign breast disease, LCIS or DCIS of contralateral breast is allowed STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:25:40 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
42358477012/16/2018 5:29:57 PMAge ≥18 years (or per national multifocal and/or bilateral early invasive breast cancer are eligible if all Patients with Stage I or IV breast cancer are not eligible STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:29:57 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423504225622/16/2018 5:35:44 PMWith Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:35:44 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423516422342/16/2018 5:35:31 PMActivity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer in women with advanced or metastatic ER+ breast cancer, who have disease that has STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:35:31 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js
423680575262/16/2018 5:28:13 PM15-20% of early breast cancers have high levels of a protein called HER2 which is that, in women receiving treatment for breast cancer, heart edema detected by MRI at STS_ListItem_GenericListhttp://www.uhn.ca/PrincessMargaret/Research/Cancer_Clinical_Research/Lists/PMCP Clinical Trials Data/AllItems.aspx0http://www.uhn.ca2/16/2018 5:28:13 PMFalse3131~sitecollection/_catalogs/masterpage/UHN/templates/PMCP_Item_Clinical_Trials.js

~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js
~sitecollection/_catalogs/masterpage/Display Templates/Search/Item_Default.js

Last reviewed:
Last modified: 6/16/2017 6:07 AM